The Section 174 Fix That Wasn't: Why House Passage Is Not Permission to Stop Capitalizing

What happened

On January 31, 2024, the House of Representatives passed the Tax Relief for American Families and Workers Act of 2024 (H.R. 7024) by a vote of 357 to 70. The bill is a bipartisan package, and its business provisions are squarely aimed at three of the most disruptive features of current law.

For research-intensive companies, the centerpiece is the § 174 provision. The bill would restore the deduction of domestic research and experimental (R&E) costs paid or incurred in tax years beginning after December 31, 2021 and before January 1, 2026 — a retroactive fix reaching back to the first year capitalization took effect, running through 2025. Foreign R&E would remain on the fifteen-year amortization schedule.

The package would also restore 100 percent bonus depreciation for property placed in service through 2025, and reinstate the more favorable EBITDA-based computation of the § 163(j) interest limitation. On the individual side, it would expand the refundable portion of the Child Tax Credit.

Why the law has not actually changed

A bill that passes one chamber has cleared one of several gates. The Senate has not passed H.R. 7024. No version has been enacted. And until enactment, the operative law is unchanged.

That operative law, for tax years beginning after December 31, 2021, is the TCJA's amendment to § 174: specified research and experimental expenditures must be capitalized and amortized — over five years for domestic spending, fifteen years for foreign spending, using a mid-year convention. There is no deduction in the year incurred. That is the rule that governs the returns being prepared right now.

The trap in the timing

The danger this filing season is specific and avoidable: treating House passage as a reason to file as though the fix were already in effect.

It is not hard to see the temptation. The retroactive reach of the bill means that, if enacted, it would change 2022 and 2023 treatment as well as 2024. A company that expects relief might be tempted to deduct domestic R&E now and assume the law will catch up. That is a bet on a legislative outcome, placed on a filed return — exactly the kind of position that does not hold.

If the bill passes later, the mechanism to capture the benefit will exist, whether through amended returns or a change in accounting method with a favorable adjustment. The relief, if it comes, is not lost by filing correctly under current law. But the exposure created by filing incorrectly under hoped-for law is real, immediate, and the taxpayer's to carry.

What this means for current-year decisions

For companies with significant domestic research spend, the planning posture for this year should assume current law and treat any fix as upside, not as a baseline:

• model estimated payments and taxable income on five-year amortization of domestic R&E
• coordinate the § 163(j) interest limitation on its current, less favorable EBIT-based footing
• treat bonus depreciation at its phased-down rate, not at a restored 100 percent
• preserve the documentation needed to claim the benefit cleanly if the law does change

This is not pessimism. It is the difference between anticipating a change and assuming it.

Key takeaways

• The House passed H.R. 7024 on January 31, 2024, by a vote of 357 to 70.
• The bill would retroactively restore domestic R&E expensing for 2022 through 2025, restore 100 percent bonus depreciation, and reinstate EBITDA-based § 163(j).
• None of that is law. The Senate has not acted, and current § 174 still requires five-year amortization of domestic research costs.
• Returns and estimated payments should assume current law; the fix, if enacted, is recoverable later.

What to do now

1. File and plan under current § 174.

Capitalize domestic R&E over five years on this season's returns. Do not anticipate the bill on a filed return.

2. Preserve the ability to capture relief retroactively.

Keep the records and computations that would support an amended return or method change if the law changes.

3. Watch the Senate, not the headlines.

House passage is a milestone, not an enactment. The status that matters is whether a bill becomes law.

Bottom line

A 357-vote majority is a strong signal. It is not a statute. Until the Senate acts, the responsible position is to capitalize domestic research costs as current law requires — and to be ready to move quickly if that law finally changes.